ALLMedicine™ Pituitary Macroadenomas Center
Research & Reviews 315 results
https://doi.org/10.1007/s00330-021-07950-6 10.1159/000339823 10.1530/EJE-15-0189 10.4158/EP-2018-0034 10.1007/s12022-017-9498-z 10.1210/jc.2017-00792 10.1530/ERC-14-0472 10.1148/radiol.2282020695 10.1530/ERC-14-0305 10.1007/s12020-018-1765-3 10.1038/nature11971 10.1148/radiol.2019182360 10.3174/ajnr.A5035 10.1148/radiol.2018172131 10.1002/acn3.50851 10.1007/s00401-017-1769-8 10.1002/mrm.25559 10.1109/TMI.2014.2337321 10.25259/SNI_169_2019 10.1007/s12020-018-1765-3 10.1007/s00701-015-2699-7 10.1530/EJE-17-0933 10.1055/s-2002-36708 10.1007/BF03347977 10.1002/dc.22950 10.1023/A:1009933820856 10.1111/j.1365-2265.2011.04286.x 10.1007/s12022-014-9347-2 10.1007/s00418-008-0472-1 10.1016/j.endinu.2017.05.009 10.1007/s00330-017-5100-9 10.1007/s13244-015-0403-3 10.1007/s10334-020-00842-8 10.1002/mrm.27726
European Radiology; Bai Y, Shen Y et. al.
Apr 29th, 2021 - To use magnetic resonance fingerprinting (MRF)-derived T1 and T2 values to differentiate gonadotroph from non-gonadotroph pituitary macroadenomas based on the 2017 World Health Organization classification of pituitary adenomas. A total of 57 patie...
https://doi.org/10.1007/s12020-021-02701-5 10.1001/jama.2016.19699 10.1016/j.beem.2009.05.005 10.1007/s11102-006-0412-9 10.1530/EJE-15-0967 10.1016/j.ando.2015.04.002 10.1210/jendso/bvaa021 10.1210/jcem.85.1.6309 10.1227/01.NEU.0000325725.77132.90 10.1210/jcem.84.10.6019 10.1210/jc.2008-0643 10.1016/j.ando.2015.04.005 10.1210/jc.2010-1048 10.1227/NEU.0000000000001389 10.1227/01.NEU.0000255459.14764.BA 10.1210/jc.2005-2552 10.1007/s11102-017-0854-2 10.1007/s00701-003-0174-3 10.3171/2015.1.JNS141543 10.1016/j.wneu.2017.09.194 10.1530/EJE-10-0255 10.1159/000491388 10.1210/jc.2008-0710 10.1227/00006123-199310000-00008 10.3171/2014.12.JNS141083 10.1016/B978-0-444-59602-4.00012-5 10.1210/jcem-62-6-1173 10.1530/EJE-13-0515 10.1016/j.wneu.2019.03.062 10.1007/BF03347763 10.1016/j.wneu.2017.09.192 10.1111/j.1365-2265.2010.03875.x 10.1007/s00701-013-1959-7 10.1007/s11102-011-0347-7 10.1002/1097-0142(19910815)68:4<860::aid-cncr2820680431>3.0.co;2-4 10.3171/jns.1984.61.3.0577 10.1007/s11102-020-01045-z 10.1111/j.1365-2265.2009.03583.x 10.1016/j.wneu.2016.04.059 10.4414/smw.2012.13680 10.1016/j.wneu.2016.02.059 10.1111/cen.13365
Endocrine Alexopoulou O, Everard V et. al.
Apr 14th, 2021 - Nonfunctionning pituitary macroadenomas (NFPMA) are benign tumors that cause symptoms of mass effects including hypopituitarism. Their primary treatment is transsphenoidal surgery. We aimed to determine the outcome of pituitary hormone deficits af...
https://doi.org/10.1007/s12020-021-02713-1 10.3171/2014.5.JNS131819 10.1002/cncr.20412 10.1530/EJE-15-0189 10.1056/NEJMra1810772 10.1007/s11102-010-0253-4 10.1227/NEU.0000000000001389 10.1210/jc.2008-0643 10.1227/01.neu.0000159647.64275.9d 10.1016/j.ando.2015.04.002 10.1001/jama.2016.19699 10.3171/2019.8.JNS191012 10.3171/2018.5.JNS181054 10.1007/s42000-019-00109-5 10.3171/2018.4.JNS172148 10.1111/cen.13791 10.1046/j.1365-2265.1998.00393.x 10.1159/000339823 10.1111/j.1365-2265.2009.03583.x 10.4103/0028-3886.287675 10.3171/2020.3.FOCUS20114 10.1007/s11102-019-00982-8 10.1016/j.wneu.2018.08.043 10.1530/EJE-11-0566 10.1530/EJE-17-0965 10.1111/cen.13365 10.1007/s12020-017-1447-6 10.1016/j.wneu.2019.04.250 10.1007/s12020-020-02455-6 10.3171/2015.1.JNS141543 10.1227/01.NEU.0000325725.77132.90 10.1016/j.wneu.2016.02.059 10.1016/j.neucir.2019.03.003 10.1177/000348940911800905
Endocrine Subramanian V, Lee RSM et. al.
Apr 6th, 2021 - Non-functioning pituitary macroadenomas (NFPAs) with visual field defects are ideally managed by transsphenoidal tumour resection to improve vision, and long-term postsurgical follow up is necessary to monitor for tumour recurrence. Regular update...
https://doi.org/10.1016/j.ejso.2021.02.004
European Journal of Surgical Oncology : the Journal of Th... Shimony N, Popovits N et. al.
Feb 27th, 2021 - Pituitary surgery has shifted in recent years from microscopic surgery(MS) to endoscopic endonasal surgery (EES). However, the comparative long-term outcome of these surgical approaches, including the need for subsequent re-operation has never bee...
https://doi.org/10.1097/WNO.0000000000001155
Journal of Neuro-ophthalmology : the Official Journal of ... Lang ST, Ryu WHA et. al.
Jan 5th, 2021 - Patients presenting with visual impairment secondary to pituitary macroadenomas often experience variable recovery after surgery. Several factors may impact visual outcomes including the extent of neuroaxonal damage in the afferent visual pathway ...
Clinicaltrials.gov 315 results
https://doi.org/10.1007/s00330-021-07950-6 10.1159/000339823 10.1530/EJE-15-0189 10.4158/EP-2018-0034 10.1007/s12022-017-9498-z 10.1210/jc.2017-00792 10.1530/ERC-14-0472 10.1148/radiol.2282020695 10.1530/ERC-14-0305 10.1007/s12020-018-1765-3 10.1038/nature11971 10.1148/radiol.2019182360 10.3174/ajnr.A5035 10.1148/radiol.2018172131 10.1002/acn3.50851 10.1007/s00401-017-1769-8 10.1002/mrm.25559 10.1109/TMI.2014.2337321 10.25259/SNI_169_2019 10.1007/s12020-018-1765-3 10.1007/s00701-015-2699-7 10.1530/EJE-17-0933 10.1055/s-2002-36708 10.1007/BF03347977 10.1002/dc.22950 10.1023/A:1009933820856 10.1111/j.1365-2265.2011.04286.x 10.1007/s12022-014-9347-2 10.1007/s00418-008-0472-1 10.1016/j.endinu.2017.05.009 10.1007/s00330-017-5100-9 10.1007/s13244-015-0403-3 10.1007/s10334-020-00842-8 10.1002/mrm.27726
European Radiology; Bai Y, Shen Y et. al.
Apr 29th, 2021 - To use magnetic resonance fingerprinting (MRF)-derived T1 and T2 values to differentiate gonadotroph from non-gonadotroph pituitary macroadenomas based on the 2017 World Health Organization classification of pituitary adenomas. A total of 57 patie...
https://doi.org/10.1007/s12020-021-02701-5 10.1001/jama.2016.19699 10.1016/j.beem.2009.05.005 10.1007/s11102-006-0412-9 10.1530/EJE-15-0967 10.1016/j.ando.2015.04.002 10.1210/jendso/bvaa021 10.1210/jcem.85.1.6309 10.1227/01.NEU.0000325725.77132.90 10.1210/jcem.84.10.6019 10.1210/jc.2008-0643 10.1016/j.ando.2015.04.005 10.1210/jc.2010-1048 10.1227/NEU.0000000000001389 10.1227/01.NEU.0000255459.14764.BA 10.1210/jc.2005-2552 10.1007/s11102-017-0854-2 10.1007/s00701-003-0174-3 10.3171/2015.1.JNS141543 10.1016/j.wneu.2017.09.194 10.1530/EJE-10-0255 10.1159/000491388 10.1210/jc.2008-0710 10.1227/00006123-199310000-00008 10.3171/2014.12.JNS141083 10.1016/B978-0-444-59602-4.00012-5 10.1210/jcem-62-6-1173 10.1530/EJE-13-0515 10.1016/j.wneu.2019.03.062 10.1007/BF03347763 10.1016/j.wneu.2017.09.192 10.1111/j.1365-2265.2010.03875.x 10.1007/s00701-013-1959-7 10.1007/s11102-011-0347-7 10.1002/1097-0142(19910815)68:4<860::aid-cncr2820680431>3.0.co;2-4 10.3171/jns.1984.61.3.0577 10.1007/s11102-020-01045-z 10.1111/j.1365-2265.2009.03583.x 10.1016/j.wneu.2016.04.059 10.4414/smw.2012.13680 10.1016/j.wneu.2016.02.059 10.1111/cen.13365
Endocrine Alexopoulou O, Everard V et. al.
Apr 14th, 2021 - Nonfunctionning pituitary macroadenomas (NFPMA) are benign tumors that cause symptoms of mass effects including hypopituitarism. Their primary treatment is transsphenoidal surgery. We aimed to determine the outcome of pituitary hormone deficits af...
https://doi.org/10.1007/s12020-021-02713-1 10.3171/2014.5.JNS131819 10.1002/cncr.20412 10.1530/EJE-15-0189 10.1056/NEJMra1810772 10.1007/s11102-010-0253-4 10.1227/NEU.0000000000001389 10.1210/jc.2008-0643 10.1227/01.neu.0000159647.64275.9d 10.1016/j.ando.2015.04.002 10.1001/jama.2016.19699 10.3171/2019.8.JNS191012 10.3171/2018.5.JNS181054 10.1007/s42000-019-00109-5 10.3171/2018.4.JNS172148 10.1111/cen.13791 10.1046/j.1365-2265.1998.00393.x 10.1159/000339823 10.1111/j.1365-2265.2009.03583.x 10.4103/0028-3886.287675 10.3171/2020.3.FOCUS20114 10.1007/s11102-019-00982-8 10.1016/j.wneu.2018.08.043 10.1530/EJE-11-0566 10.1530/EJE-17-0965 10.1111/cen.13365 10.1007/s12020-017-1447-6 10.1016/j.wneu.2019.04.250 10.1007/s12020-020-02455-6 10.3171/2015.1.JNS141543 10.1227/01.NEU.0000325725.77132.90 10.1016/j.wneu.2016.02.059 10.1016/j.neucir.2019.03.003 10.1177/000348940911800905
Endocrine Subramanian V, Lee RSM et. al.
Apr 6th, 2021 - Non-functioning pituitary macroadenomas (NFPAs) with visual field defects are ideally managed by transsphenoidal tumour resection to improve vision, and long-term postsurgical follow up is necessary to monitor for tumour recurrence. Regular update...
https://doi.org/10.1016/j.ejso.2021.02.004
European Journal of Surgical Oncology : the Journal of Th... Shimony N, Popovits N et. al.
Feb 27th, 2021 - Pituitary surgery has shifted in recent years from microscopic surgery(MS) to endoscopic endonasal surgery (EES). However, the comparative long-term outcome of these surgical approaches, including the need for subsequent re-operation has never bee...
https://doi.org/10.1097/WNO.0000000000001155
Journal of Neuro-ophthalmology : the Official Journal of ... Lang ST, Ryu WHA et. al.
Jan 5th, 2021 - Patients presenting with visual impairment secondary to pituitary macroadenomas often experience variable recovery after surgery. Several factors may impact visual outcomes including the extent of neuroaxonal damage in the afferent visual pathway ...
